September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice President Louise Bouman reported for us from both congresses. This month also brought promising clinical trial results, new research on a wide range of topics, from treatment decisions to cognitive symptoms, and news from patient communities around the world. On our side, we held our webinar on how science and artificial intelligence can improve pulmonary arterial hypertension care, and launched five new PEP Talks.
As always, the platform brings together the latest science, patient resources and community news, freely available to all. If you haven’t joined yet, we warmly invite you to do so. 🌍
👇 Scroll down for the full September highlights, organised by category.
🎤 Alliance for Pulmonary Hypertension — News and Events
- Reporting from the European Society of Cardiology and European Respiratory Society Annual Congresses 2026 — Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension
- Webinar on how the advances in science and artificial intelligence can improve pulmonary arterial hypertension care — a prestigious panel of speakers shared expert insights on how new scientific advances and artificial intelligence can improve care, September 28, 2026
- Five new PEP Talks (Patients Empowering Patients educational series), announced on September 28
đź“‹ Guidelines and Regulatory Updates
- Updated European Respiratory Society Clinical Practice Guidelines for pulmonary arterial hypertension presented at the European Respiratory Society Congress in Barcelona, September 7, 2026
- United States Food and Drug Administration updates the Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension
đź’Š Clinical Trials
- Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease
- Pulnovo Medical announces results of the PADN-HF-PH trial at the European Society of Cardiology Congress 2026, simultaneously published in The New England Journal of Medicine, September 3, 2026
🔬 Research and Reviews
- Factors influencing treatment decisions in patients with pulmonary arterial hypertension — Deutsche Medizinische Wochenschrift, September 9, 2026
- Randomised controlled trial on fluid restriction in pulmonary arterial hypertension — Respiration, September 9, 2026
- A familiar drug in unfamiliar territory: will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension? — Journal of Heart and Lung Transplantation, September 3, 2026
- Reduced brain blood flow, heart strain and cognitive symptoms in pulmonary arterial hypertension — Therapeutic Advances in Respiratory Disease, 2026
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review — European Respiratory Journal, Volume 68, Issue 1
🌍 Patient Community and Associations
- Patients and advocates call on the United States Congress to pass life-changing oxygen reform before the end of the year
- The French Pulmonary Hypertension Association celebrates its 30th anniversary at its 6th Patient Congress, 13–15 November 2026
- Taking the plunge for patients 🏊 — pulmonary hypertension nurses Iain Armstrong and Javier Jimenez swam 1,609 metres in London’s Hyde Park for “Swim Serpentine” on September 19
Curated by the Alliance for Pulmonary Hypertension | PH Knowledge Sharing Platform